Cancer Innova Program
Collaboration to support innovation in cancer and accelerate the translation of research to patients.
The Cancer Innova Program (CIP) is an inclusive collaboration in which public and private entities jointly participate to promote innovation in cancer. To this end, a drug discovery program has been created aligned with the Cancer Mission of the Horizon Europe framework program, which represents a landmark in the biotechnology sector.
Accelerating drug discovery in cancer
This project is part of the Business Factory model of the Government of Galicia. Its seed was the I2D2 program, a collaboration between GAIN, Kaertor Foundation and Janssen/ J&J, which incubated early research projects in new drug discovery and validated a new incubation methodology based in five validated work packages. This resulted in an 80% reduction of time and costs, compared to the industry averages.
In the Cancer Innova program, application of the most disruptive research of the highest scientific quality on cancer will be carried out, with the aim of achieving proof of concept in humans through research planned by milestones.
Who is the Cancer Innova program aimed at?
The CIP program is aimed towards researchers and public or private entities as well as small companies specialized in cancer mechanisms who want to apply their research to drug discovery.
Call & selection.
Call and EOI selection
Signing of agreements and incubation
03. & 04.
Acceleration & Consolidation.
Transfer of projects to the market
Expression of Interest form
The first selected projects to start the incubation phase will be chosen from the Expressions of Interest (EoI) received by the first two evaluation deadlines (on 21st December 2020 and on 31st January 2021 at 15:00 (CET)) although the call for proposals will remain open in the Cancer Innova website and projects received after these dates will continue to be considered.